These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa? Scarpignato C Dig Dis; 1995 Jan; 13 Suppl 1():9-39. PubMed ID: 7697906 [TBL] [Abstract][Full Text] [Related]
8. Treatment and prevention of nonsteroidal anti-inflammatory drug induced gastrointestinal mucosal injury. Agrawal NM; Dajani EZ Int J Clin Pharmacol Res; 1989; 9(6):347-57. PubMed ID: 2576801 [TBL] [Abstract][Full Text] [Related]
9. Options in the treatment and prevention of NSAID-induced gastroduodenal mucosal damage. Agrawal NM; Dajani EZ J Rheumatol Suppl; 1990 Feb; 20():7-11. PubMed ID: 1969964 [TBL] [Abstract][Full Text] [Related]
10. The role of H2-receptor antagonists in the prevention of NSAID-induced gastrointestinal damage. Rachmilewitz D Aliment Pharmacol Ther; 1988; 2 Suppl 1():65-73. PubMed ID: 2908758 [TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update. Dajani EZ; Agrawal NM J Physiol Pharmacol; 1995 Mar; 46(1):3-16. PubMed ID: 7599335 [TBL] [Abstract][Full Text] [Related]
12. How do non-steroidal anti-inflammatory drugs affect gastric mucosal defenses? Fromm D Clin Invest Med; 1987 May; 10(3):251-8. PubMed ID: 3304754 [TBL] [Abstract][Full Text] [Related]
13. Protective effects of prostaglandins against nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Dajani EZ; Agrawal NM Int J Clin Pharmacol Res; 1989; 9(6):359-69. PubMed ID: 2699464 [TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C; Pelosini I Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472 [TBL] [Abstract][Full Text] [Related]
15. Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDS). Rationale and clinical implications. Hayllar J; Macpherson A; Bjarnason I Drug Saf; 1992; 7(2):86-105. PubMed ID: 1605904 [TBL] [Abstract][Full Text] [Related]
16. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. Lad R; Armstrong D Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432 [TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. McCarthy DM Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039 [TBL] [Abstract][Full Text] [Related]
18. Ulcerogenic drugs and antiulcer compounds: effects on gastroduodenal mucosa. Johansson C Scand J Gastroenterol Suppl; 1987; 128():24-32. PubMed ID: 3477002 [TBL] [Abstract][Full Text] [Related]
19. Treatment of nonsteroidal anti-inflammatory drug-associated gastric and duodenal damage. Efficacy of antisecretory drugs and mucosal protective compounds. Pipkin G; Mills JG Dig Dis; 1995 Jan; 13 Suppl 1():75-88. PubMed ID: 7697904 [TBL] [Abstract][Full Text] [Related]